

## Product datasheet for **TL303918V**

### INPP5E Human shRNA Lentiviral Particle (Locus ID 56623)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	INPP5E Human shRNA Lentiviral Particle (Locus ID 56623)
Locus ID:	56623
Synonyms:	CORS1; CPD4; JBTS1; MORMS; pharbin; PPI5PIV
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	INPP5E - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_001318502</a> , <a href="#">NM_019892</a> , <a href="#">NM_019892.1</a> , <a href="#">NM_019892.2</a> , <a href="#">NM_019892.3</a> , <a href="#">NM_019892.4</a> , <a href="#">NM_019892.5</a> , <a href="#">BC028032</a> , <a href="#">BC028032.1</a> , <a href="#">BC110356</a> , <a href="#">NM_019892.6</a>
UniProt ID:	<a href="#">Q9NRR6</a>
Summary:	The protein encoded by this gene is an inositol 1,4,5-trisphosphate (InsP3) 5-phosphatase. InsP3 5-phosphatases hydrolyze Ins(1,4,5)P3, which mobilizes intracellular calcium and acts as a second messenger mediating cell responses to various stimulation. Studies of the mouse counterpart suggest that this protein may hydrolyze phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,5-bisphosphate on the cytoplasmic Golgi membrane and thereby regulate Golgi-vesicular trafficking. Mutations in this gene cause Joubert syndrome; a clinically and genetically heterogenous group of disorders characterized by midbrain-hindbrain malformation and various associated ciliopathies that include retinal dystrophy, nephronophthisis, liver fibrosis and polydactyly. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jan 2016]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).